QIAGEN and Natera to Develop Cutting-Edge Pre-Natal Genetic Testing Assays
Non-invasive, cell-free pre-natal DNA testing to be performed on QIAGEN’s GeneReader NGS System
Non-invasive, cell-free pre-natal DNA testing to be performed on QIAGEN’s GeneReader NGS System
aLF Reader and ImplantSafeDR test accurately detect damaging inflammation earlier than traditional methods to better protect dental implants
Convenient blood test uses novel technology to test for recurrence of tumors by detecting circulating DNA
Findings indicate increased specificity in low-risk populations and potential for monitoring tuberculosis treatment
QIAGEN’s GeneReader NGS System Gains Further Validation in Oncology Research Applications with New Independent Performance Review Data
Public-private partnership aims to standardize and clinically validate blood-based biomarkers
New biomarker test designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer
Selected for screening of 340,000 recruits in 2017 as part of national TB control strategy
European launch of the new CE marked ipsogen CALR RGQ PCR Kit to improve MPN diagnosis for leukemia patients, in line with latest WHO recommendations and clinical guidelines
PAXgene Blood ccfDNA enhances handling and workflow convenience for liquid biopsy applications in prenatal testing and cancer research
Project that measured pathogens in New York City subways goes global this summer
New follow-up assay helps stratify patients with transforming HPV infections